Literature DB >> 16919578

Myocardial oxidative metabolic supply-demand relationships in patients with nonischemic dilated cardiomyopathy.

Marvin W Kronenberg1, Gerald I Cohen, Marlo F Leonen, Thomas A Mladsi, Marcelo F Di Carli.   

Abstract

BACKGROUND: Nonischemic dilated cardiomyopathy (NIDCM) is associated with left ventricular remodeling, hypertrophy, and mitochondrial metabolic abnormalities in vitro. We evaluated the hypothesis that energy supply, as judged by the rate of myocardial oxidative metabolism, is inadequate to meet oxygen demand in patients with NIDCM compared with normal subjects. METHODS AND
RESULTS: We used positron emission tomography to determine the myocardial carbon 11 acetate decay rate (kmono) as an index of energy supply, and we compared kmono with the rate-pressure product (RPP) as an index of metabolic demand in 7 patients with NIDCM and 7 normal subjects. The mean kmono value (SEM) was 0.060 +/- 0.006 min(-1) in NIDCM patients versus 0.054 +/- 0.002 in normal subjects (P = not significant). The RPP was 9949 +/- 931 beats/min.mm Hg in NIDCM patients and 6521 +/- 476 in normal subjects (P = .007). The relationship of kmono to this index of demand (kmono/RPP) was 6.2 x 10(-6) in NIDCM patients but was 8.5 x 10(-6) in normal subjects (P = .003). Thus RPP, as an index of myocardial oxygen demand, was poorly matched by the rate of oxidative metabolism in those patients with NIDCM. The kmono was closely related to RPP in normal subjects (r = 0.83, P = .02) but not in NIDCM patients. Furthermore, there was no significant relationship between kmono and wall stress as another index of oxygen demand.
CONCLUSIONS: These results are consistent with a mitochondrial metabolic abnormality in heart failure. This metabolic mismatch detected by positron emission tomography may contribute to the pathophysiology of congestive heart failure and left ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919578     DOI: 10.1016/j.nuclcard.2006.04.002

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  54 in total

1.  Noninvasive measurements of myocardial oxygen consumption--can we do better?

Authors:  Robert J Gropler
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

2.  Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus.

Authors:  M F Di Carli; D Bianco-Batlles; M E Landa; A Kazmers; H Groehn; O Muzik; G Grunberger
Journal:  Circulation       Date:  1999-08-24       Impact factor: 29.690

3.  Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy.

Authors:  A F Quigley; R M Kapsa; D Esmore; G Hale; E Byrne
Journal:  J Card Fail       Date:  2000-03       Impact factor: 5.712

4.  Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat.

Authors:  P Anversa; G Olivetti; M Melissari; A V Loud
Journal:  J Mol Cell Cardiol       Date:  1980-08       Impact factor: 5.000

5.  Delineation of myocardial oxygen utilization with carbon-11-labeled acetate.

Authors:  M Brown; D R Marshall; B E Sobel; S R Bergmann
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

6.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

7.  Abnormal mitochondrial respiration in failed human myocardium.

Authors:  V G Sharov; A V Todor; N Silverman; S Goldstein; H N Sabbah
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

8.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

9.  Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy.

Authors:  R S Beanlands; D S Bach; R Raylman; W F Armstrong; V Wilson; M Montieth; C K Moore; E Bates; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

10.  Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease.

Authors:  M Corral-Debrinski; G Stepien; J M Shoffner; M T Lott; K Kanter; D C Wallace
Journal:  JAMA       Date:  1991-10-02       Impact factor: 56.272

View more
  6 in total

1.  Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy.

Authors:  Susan P Bell; Douglas W Adkisson; Henry Ooi; Douglas B Sawyer; Mark A Lawson; Marvin W Kronenberg
Journal:  J Card Fail       Date:  2013-10-29       Impact factor: 5.712

2.  11C-acetate PET: A powerful tool to analyze metabolic and functional changes in the heart related to alcohol consumption.

Authors:  John C Stendahl; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2020-07-16       Impact factor: 5.952

3.  Loss of ATP-Sensitive Potassium Channel Surface Expression in Heart Failure Underlies Dysregulation of Action Potential Duration and Myocardial Vulnerability to Injury.

Authors:  Zhan Gao; Ana Sierra; Zhiyong Zhu; Siva Rama Krishna Koganti; Ekaterina Subbotina; Ankit Maheshwari; Mark E Anderson; Leonid V Zingman; Denice M Hodgson-Zingman
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

Review 4.  Silent disease progression in clinically stable heart failure.

Authors:  Hani N Sabbah
Journal:  Eur J Heart Fail       Date:  2016-12-14       Impact factor: 15.534

5.  Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension.

Authors:  Evan L Brittain; Kevin Niswender; Vineet Agrawal; Xinping Chen; Run Fan; Meredith E Pugh; Todd W Rice; Ivan M Robbins; Haocan Song; Christopher Thompson; Fei Ye; Chang Yu; He Zhu; James West; John H Newman; Anna R Hemnes
Journal:  J Am Heart Assoc       Date:  2020-11-10       Impact factor: 5.501

6.  Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.

Authors:  Susan P Bell; Douglas W Adkisson; Mark A Lawson; Li Wang; Henry Ooi; Douglas B Sawyer; Marvin W Kronenberg
Journal:  J Am Heart Assoc       Date:  2014-08-27       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.